Publishing research using ab52587? Please let us know so that we can cite the reference in this datasheet.

ab52587 has been referenced in 78 publications.

  • Maruse Y  et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg N/A:N/A (2018). IHC-P ; Human . PubMed: 29395669
  • Balzano T  et al. The Cerebellum of Patients with Steatohepatitis Shows Lymphocyte Infiltration, Microglial Activation and Loss of Purkinje and Granular Neurons. Sci Rep 8:3004 (2018). PubMed: 29445232
  • Takada K  et al. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 16:86 (2018). IHC-P ; Human . PubMed: 29615076
  • Huang F  et al. MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. Oncol Lett 15:4797-4804 (2018). PubMed: 29552119
  • Hurabielle C  et al. Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. Hum Pathol 71:100-108 (2018). IHC-P ; Human . PubMed: 29107664
  • Klepsch V  et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun 9:1538 (2018). PubMed: 29670099
  • Owen D  et al. Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. J Thorac Oncol N/A:N/A (2018). Human . PubMed: 29702286
  • Asano Y  et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med 16:87 (2018). IHC-P . PubMed: 29615063
  • Rojkó L  et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol N/A:N/A (2018). Human . PubMed: 29675791
  • Chang H  et al. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. J Gynecol Oncol 29:e27 (2018). IHC-P ; Human . PubMed: 29400020
  • Brcic L  et al. Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. Virchows Arch 472:589-598 (2018). PubMed: 29520483
  • Su H  et al. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer 121:18-24 (2018). IHC-P ; Human . PubMed: 29858021
  • Ye Q  et al. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer. Hum Pathol 75:81-90 (2018). IHC-P . PubMed: 29447919
  • Jennewein L  et al. Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors. Oncol Lett 15:9852-9860 (2018). PubMed: 29928359
  • Kunimasa K  et al. Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. Invest New Drugs N/A:N/A (2018). PubMed: 29947012
  • Matsuda K  et al. Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. Clin Exp Med N/A:N/A (2018). PubMed: 29961175
  • Miyamoto E  et al. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. J Surg Oncol 117:1405-1412 (2018). IHC ; Human . PubMed: 29663398
  • Kaewkangsadan V  et al. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC. BMC Cancer 18:123 (2018). IHC-P ; Human . PubMed: 29390966
  • An HJ  et al. Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med 52:9-13 (2018). PubMed: 28994272
  • Vermeulen JF  et al. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. Oncoimmunology 7:e1398877 (2018). PubMed: 29399402
  • Zhao Z  et al. CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. Oncotarget 9:5208-5215 (2018). PubMed: 29435173
  • Quaranta V  et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res 78:4253-4269 (2018). PubMed: 29789416
  • Fontugne J  et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8:24644-24651 (2017). IHC-P ; Human . PubMed: 28445951
  • Balermpas P  et al. Human papilloma virus load and PD-1/PD-L1, CD8+and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology 6:e1288331 (2017). PubMed: 28405521
  • Ness N  et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 8:26789-26801 (2017). PubMed: 28460462
  • Gao Y  et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chin J Cancer 36:61 (2017). PubMed: 28754154
  • Greisen SR  et al. Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis. Front Immunol 8:851 (2017). PubMed: 28791012
  • Wu Y  et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 8:64066-64082 (2017). PubMed: 28969052
  • Okabe M  et al. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci 108:81-90 (2017). IHC-P ; Human . PubMed: 27801993
  • Kammerer-Jacquet SF  et al. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. Int J Cancer 140:142-148 (2017). PubMed: 27623354
  • Sato Y  et al. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma. Pathol Int N/A:N/A (2017). IHC-P, IF ; Human . PubMed: 28139862
  • Amaya CN  et al. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies. Pathology 49:292-296 (2017). IHC-P ; Human . PubMed: 28238417
  • Chovanec M  et al. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget 8:21794-21805 (2017). IHC-P ; Human . PubMed: 28423520
  • Balermpas P  et al. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 141:594-603 (2017). IHC ; Human . PubMed: 28480996
  • Chew V  et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 114:E5900-E5909 (2017). Human . PubMed: 28674001
  • Chang H  et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther 10:2983-2992 (2017). IHC-P ; Human . PubMed: 28652780
  • Shen T  et al. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep 7:7848 (2017). IHC-P, IF ; Human . PubMed: 28798308
  • Nguyen TB  et al. Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7:e516 (2017). IHC-Fr ; Human . PubMed: 28157189
  • Veras E  et al. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int J Gynecol Pathol 36:146-153 (2017). PubMed: 27362903
  • Zhang SA  et al. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. Tumour Biol 39:1010428317692237 (2017). PubMed: 28351328
  • Cierna Z  et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol 27:300-5 (2016). IHC-P ; Human . PubMed: 26598537
  • Nagata Y  et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 127:596-604 (2016). IHC . PubMed: 26574607
  • Li X  et al. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. Am J Clin Pathol 146:496-502 (2016). PubMed: 27686176
  • Bastman JJ  et al. Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab N/A:jc20154227 (2016). IHC-P ; Human . PubMed: 27045886
  • Li CW  et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632 (2016). PubMed: 27572267
  • Dronca RS  et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 1:N/A (2016). IHC-P ; Human . PubMed: 27182556
  • Paulsen EE  et al. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin Lung Cancer N/A:N/A (2016). WB, IHC-P ; Human . PubMed: 27816392
  • Kaewkangsadan V  et al. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res 2016:4757405 (2016). IHC-P ; Human . PubMed: 27777963
  • Chang H  et al. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget 7:80426-80434 (2016). IHC-P ; Human . PubMed: 27741514
  • Leng C  et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8? T cells. Oncol Rep 35:699-708 (2016). PubMed: 26718132
  • Calderaro J  et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology 64:2038-2046 (2016). PubMed: 27359084
  • Schultheis AM  et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51:421-6 (2015). IHC ; Human . PubMed: 25582496
  • Tamura T  et al. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. Anticancer Res 35:5369-76 (2015). IHC-P ; Human . PubMed: 26408698
  • Laurent C  et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology 4:e1026530 (2015). IHC . PubMed: 26405585
  • Schmidt LH  et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One 10:e0136023 (2015). PubMed: 26313362
  • Gao F & Wang W MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep 11:1200-6 (2015). PubMed: 25369914
  • Joseph RW  et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 3:18-22 (2015). PubMed: 25287118
  • Mishra V  et al. Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse. Int J Physiol Pathophysiol Pharmacol 7:87-97 (2015). PubMed: 26330898
  • Kiyasu J  et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193-201 (2015). IHC-P ; Human . PubMed: 26239088
  • Cheng L  et al. Monoclonal antibodies specific to human ?42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs 7:620-9 (2015). Flow Cyt ; Mouse . PubMed: 25692916
  • Yang ZZ  et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J 5:e281 (2015). IHC-P, Flow Cyt ; Human . PubMed: 25700246
  • Smeltzer JP  et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res 20:2862-72 (2014). PubMed: 24727328
  • Cogbill CH  et al. Utility of CD279/PD-1 immunohistochemistry in the evaluation of benign and neoplastic T-cell-rich bone marrow infiltrates. Am J Clin Pathol 142:88-98 (2014). PubMed: 24926091
  • Argüello RJ  et al. Presence of antigen-experienced T cells with low grade of differentiation and proliferative potential in chronic Chagas disease myocarditis. PLoS Negl Trop Dis 8:e2989 (2014). IHC-P ; Human . PubMed: 25144227
  • Szabo K  et al. The histopathology of labial salivary glands in primary Sjögren's syndrome: focusing on follicular helper T cells in the inflammatory infiltrates. Mediators Inflamm 2014:631787 (2014). IHC-P ; Human . PubMed: 25177110
  • Verstegen RH  et al. Defective B-cell memory in patients with Down syndrome. J Allergy Clin Immunol 134:1346-1353.e9 (2014). PubMed: 25159464
  • Liarski VM  et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci Transl Med 6:230ra46 (2014). Human . PubMed: 24695686
  • Behr DS  et al. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int J Clin Exp Pathol 7:7610-21 (2014). PubMed: 25550797
  • Kang MJ  et al. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl Oncol 6:282-9 (2013). IHC-P ; Human . PubMed: 23730407
  • Sato F  et al. Angioimmunoblastic T-cell lymphoma mice model. Leuk Res 37:21-7 (2013). IHC-P ; Human . PubMed: 23026775
  • Sznol M & Chen L Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021-34 (2013). PubMed: 23460533
  • Kim JR  et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8:e82870 (2013). IHC-P ; Human . PubMed: 24349382
  • Germanidis G  et al. Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation. Front Immunol 4:207 (2013). PubMed: 23898331
  • French JD  et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 97:E934-43 (2012). IHC-P ; Human . PubMed: 22466343
  • Miyoshi H  et al. Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders. Am J Clin Pathol 137:879-89 (2012). PubMed: 22586046
  • Bruneau J  et al. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol 177:570-4 (2010). IHC-Fr ; Human . PubMed: 20566750
  • Wada N  et al. Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. Virchows Arch 455:285-93 (2009). IHC-P ; Human . PubMed: 19727807
  • Roncador G  et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 92:1059-66 (2007). PubMed: 17640856

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up